title: CD18/CD54(+CD102), CD2/CD58 pathway-independent killing of lymphokine-activated killer (LAK) cells against glioblastoma cell lines T98G and U373MG.
abstract: For natural killer cell-mediated cytolysis (NK-lysis) and lymphokine-activated killer cell-mediated cytolysis (LAK-lysis), the co-stimulatory signals of CD18/CD54(+CD102) and CD2/CD58 pathways are essential. However, in this report, we describe a LAK-lysis that does not depend upon these two pathways. The killed cells were glioblastoma cell lines T98G and U373MG. The LAK cells were induced from peripheral blood lymphocytes in the presence of interleukin-2. 1) The T98G and U373MG did not express CD54 or CD102, but expressed CD58. 2) However, when they were pretreated with an anti-CD58 (TS2/9), the LAK-lysis was not blocked. 3) The LAK-lysis was markedly inhibited by pretreating with Concanamycin A and slightly inhibited by treating with antitumor necrosis factor-related apoptosis-inducing ligand (anti-TRAIL) antibody. 4) Nineteen percent of the LAK cells adhered to the T98G. The adhered LAK cells killed it. But nonadherent LAK cells could not kill the T98G or U373MG but killed lymphoblastoma cell lines Raji and NALM-6. These findings suggested that this type of the LAK-lysis might not depend upon the CD18/CD54(+CD102) pathway or CD2/CD58 pathway. The effector cells that killed the T98G and U373MG might not always be the same as the effector cells that killed the other cell lines. The LAK cells contain several subsets, and one of the subsets might kill these two target cell lines.
authors.affiliation: Blood Transfusion Service, School of Medicine, Tokyo Medical and Dental University, Japan.
authors.forename: F
authors.initials: F
authors.lastname: Komatsu
authors.forename: M
authors.initials: M
authors.lastname: Kajiwara
mesh_terms: D015703:Antigens, CD / Q000276:immunology*; D018821:CD18 Antigens / Q000276:immunology; D018801:CD2 Antigens / Q000276:immunology; D018968:CD58 Antigens / Q000276:immunology; D002448:Cell Adhesion; D015815:Cell Adhesion Molecules / Q000276:immunology; D002857:Chromium / Q000737:chemistry; D003602:Cytotoxicity, Immunologic; D005909:Glioblastoma / Q000276:immunology*; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000276:immunology; D007371:Interferon-gamma / Q000096:biosynthesis; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D007694:Killer Cells, Natural / Q000276:immunology; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology; D014407:Tumor Cells, Cultured / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: D015703:Antigens, CD; D018821:CD18 Antigens; D018801:CD2 Antigens; D018968:CD58 Antigens; D015815:Cell Adhesion Molecules; C065289:ICAM2 protein, human; D014409:Tumor Necrosis Factor-alpha; D002857:Chromium; D018799:Intercellular Adhesion Molecule-1; D007371:Interferon-gamma